Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 2 | 50.5% | +53.9% |
| SHI, GENBIN | 1 | — | — |
| BORALSKY, LUKE ALAN | 1 | 100.0% | +0.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 76.6% | +34.8% |
| HERNANDEZ, JACKSON J | 1 | 50.9% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 9d |
| 18682227 | USE OF ENSARTINIB OR SALT THEREOF IN TREATMENT OF DISEASE CARRYING MET 14 EXON SKIPPING MUTATION | SHI, GENBIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559682 | Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use Thereof | HEASLEY, MEGHAN CHRISTINE | 28d overdue |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | HERNANDEZ, JACKSON J | 55d |
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | — |
| 18294516 | ANTI-PD-L1 NANOBODY AND USE THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1624 | 1 |
| 1626 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18682227 | USE OF ENSARTINIB OR SALT THEREOF IN TREATMENT OF DISEASE CARRYING MET 14 EXON SKIPPING MUTATION | SHI, GENBIN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18294516 | ANTI-PD-L1 NANOBODY AND USE THEREOF | HADDAD, MAHER M | — | §112DP | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 1624 | §103§112 | Non-Final OA | 9d | Pending | Dec 20, 2023 |
| 18559682 | Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use Thereof | HEASLEY, MEGHAN CHRISTINE | 1626 | §112 | Non-Final OA | 28d overdue | Pending | Nov 08, 2023 |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | 55d | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial